Weekly injectionFDA-approved
Wegovy® pen
Semaglutide, a GLP-1-only injection with a higher-dose HD option for eligible patients.
Learn MorePrescription Weight Management
Real, substantial weight loss. Once a week.
Tirzepatide injection · by Eli Lilly
Zepbound® (tirzepatide) is the once-weekly, FDA-approved treatment that targets two appetite-regulating pathways — with a licensed provider guiding your dose and your plan from day one.
- Clinically studied weight-loss results — see the data below
- Once-weekly tirzepatide treatment
- Dual GIP + GLP-1 receptor activity, provider-guided dosing
Prescription only. Treatment is provided only when a licensed clinician determines it is clinically appropriate. Individual results vary.
1 / 3
Real life, weekly rhythm
One injection a week, on your schedule
Brand-name Zepbound®, prescribed online and shipped to your door through licensed pharmacy partners.
- Type
- GIP/GLP-1 injection
- Frequency
- Once weekly
- Status
- FDA-approved
- Manufacturer
- Eli Lilly
- Active ingredient
- Tirzepatide
Overview
Meet Zepbound®
A once-weekly tirzepatide injection FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition, alongside diet and exercise.
FDA-approved
Approved for chronic weight management alongside diet and exercise.
Dual GIP + GLP-1
The first weight-management medication to activate both receptor pathways.
Once-weekly injection
Same day each week, any time of day, with or without food.
Provider-guided dosing
A licensed provider titrates your dose and stays with you.
Mechanism
How Zepbound® works
Tirzepatide targets GIP and GLP-1 receptors to help curb hunger and support weight loss.
Inject once weekly
A prefilled, single-use pen delivers tirzepatide under the skin.
Activates GIP + GLP-1 receptors
Two incretin pathways involved in appetite, fullness, and how the body handles food.
Helps you feel fuller faster and longer
Digestion slows and hunger signals quiet, so smaller portions feel natural.
Supports weight loss with diet and exercise
Alongside a reduced-calorie eating pattern and increased physical activity.
Clinical evidence
Clinically proven weight-loss support
Substantial average weight reduction was demonstrated in clinical trials. Your provider chooses the dose based on response and tolerability, and no specific outcome is guaranteed.
15 mg maintenance dose
20.9%
average body-weight loss at 72 weeks (SURMOUNT-1 trial).*
Placebo
3.1%
average body-weight loss at 72 weeks in the same trial.*
- Once-weekly tirzepatide
- Used with diet and exercise
- FDA-approved for chronic weight management
*Average 20.9% body weight loss at 72 weeks on the 15 mg dose, versus 3.1% for placebo, based on the SURMOUNT-1 clinical trial in adults with obesity or overweight plus a weight-related condition, alongside a reduced-calorie diet and increased physical activity. Individual results vary; no specific outcome is guaranteed.
Dosing
A gradual, provider-guided schedule.
Zepbound® starts low and steps up no faster than every four weeks. Your provider chooses the dose based on response and tolerability.
Starting
2.5 mg
weekly
Step 1
5 mg
weekly
Step 2
7.5 mg
weekly
Step 3
10 mg
weekly
Step 4
12.5 mg
weekly
Maximum
15 mg
weekly
Maintenance doses of 5 mg, 10 mg, or 15 mg are common. Not every patient needs the highest dose.
Your options
Zepbound® or Wegovy®?
Both are once-weekly, FDA-approved injections for chronic weight management. The key difference is the mechanism.
| Zepbound® | Wegovy® | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Receptors targeted | GIP + GLP-1 (dual) | GLP-1 only |
| Frequency | Once weekly | Once weekly |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Pen formats | Single-dose pen, KwikPen® | Single-dose pen (2.4 mg, 7.2 mg HD) |
| FDA-approved for weight management | Yes | Yes |
Some patients respond better to one mechanism than the other. Your provider helps decide which fits your history. Learn about Wegovy® pen.
Designed for a simple weekly routine
Everything you need, one pen at a time.
Prefilled, single-use pen — no mixing, no measuring; each pen is used once and disposed of safely.
Once-weekly injection — same day each week, any time of day, with or without food.
Active ingredient: tirzepatide — the FDA-approved dual GIP/GLP-1 receptor agonist studied in the SURMOUNT trials.
Prescription support — a licensed provider titrates your dose and stays with you through check-ins.
The process
Your Zepbound® treatment journey
Personalized care, every step of the way.
1.
Complete your online visit
Share your health history and goals from the comfort of home — about 10 minutes.
2.
Provider reviews and prescribes if appropriate
A licensed provider reviews your information and creates a plan that's right for you.
3.
Transparent self-pay pricing
Your total cost is confirmed before you commit — no insurance, no surprise bills.
4.
Medication shipped to your door
Brand-name Zepbound® ships discreetly through licensed pharmacy partners.
5.
Ongoing support to stay on track
Dose adjustments, check-ins, and real people who care.
Real care. Real people.
Compassionate support from our care team, when you need it.
Safe. Effective. Proven.
Zepbound® is FDA-approved for chronic weight management.
Pancreatitis
Stop use and seek care for severe, persistent abdominal pain, with or without vomiting, that may radiate to the back.
Kidney problems
Vomiting or diarrhea can cause dehydration and worsen kidney function; stay hydrated.
Gallbladder problems
Gallstones and gallbladder inflammation have been reported; watch for upper-abdominal pain, fever, or yellowing of the skin.
Low blood sugar
Risk is higher when used with insulin or sulfonylureas; know the signs of hypoglycemia.
Severe allergic reactions
Stop use and get emergency help for swelling, trouble breathing, rapid heartbeat, or severe rash.
Severe stomach or intestinal disease
Not studied in patients with severe GI disease, including severe gastroparesis.
Pregnancy & medication interactions
Do not use if pregnant or planning pregnancy. Tirzepatide may reduce the effectiveness of oral contraceptives around dose increases — talk to your provider. Also report depression or suicidal thoughts and every medication you take.
Common side effects
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite.
Provider-guided
A short checklist before your first injection.
Your provider reviews your BMI and weight-related conditions, personal and family thyroid history, pancreatitis and gallbladder history, kidney function, current medications, pregnancy plans, and what a realistic first 12 weeks looks like for you.
Questions
Zepbound® FAQ
Both are once-weekly injections approved for chronic weight management, but they are different molecules. Wegovy® (semaglutide) activates GLP-1 receptors only. Zepbound® (tirzepatide) activates both GIP and GLP-1 receptors. Some patients respond better to one mechanism than the other; your provider helps decide which fits your history.
Once a week, on the same day each week, at any time of day, with or without food. Each single-dose pen is used once and disposed of in a sharps container.
Treatment starts at 2.5 mg weekly for four weeks, then increases in 2.5 mg steps (5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg) no faster than every four weeks. Your provider chooses the maintenance dose based on your response and tolerability — not everyone needs the highest dose.
In the SURMOUNT-1 clinical trial, adults on the 15 mg maintenance dose lost an average of 20.9% of body weight at 72 weeks, versus 3.1% for placebo, alongside diet and exercise. Individual results vary and no specific outcome is guaranteed.
Graceland Wellness is fully cash-pay with transparent self-pay pricing confirmed before you commit — no insurance, no copays, no surprise bills. Medication ships directly to your door through licensed pharmacy partners.
Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection-site reactions, fatigue, and decreased appetite. These are most noticeable during dose increases and often ease with time. Serious risks are described in the safety section above.
The KwikPen® contains the same tirzepatide in a multi-dose pen that delivers four weekly doses before it is replaced. The medication, dosing schedule, and clinical evidence are identical — only the device differs.
Explore more treatments
Other FDA-approved weight-management options
Daily tabletFDA-approved
Wegovy® pill
The same semaglutide molecule in a once-daily oral tablet — no needles.
Learn MoreWeekly injectionFDA-approved
Zepbound® KwikPen®
The same tirzepatide in a multi-dose KwikPen® delivery system.
Learn MoreDaily tabletFDA-approved
Foundayo™ pill
Orforglipron, a non-peptide oral GLP-1 from Eli Lilly.
Learn MoreGet started
Weight-loss care should feel supportive, not overwhelming.
Take a private assessment and a licensed provider will tell you whether Zepbound® — or another option — fits your history, routine, and goals.
Prescription required. Zepbound® and KwikPen® are registered trademarks of Eli Lilly and Company; Wegovy® is a registered trademark of Novo Nordisk A/S. Graceland Wellness is not affiliated with either manufacturer. Transparent self-pay pricing; medication ships directly to your door.